Drug
Ibritumomab tiuxetan clinical trials
Also written Zevalin and IDEC-Y2B8.
Includes 8 studies of Yttrium Y-90 ibritumomab tiuxetan.
- studies test it
- 51
- open now
- 0
- in phase 3
- 8
- first study started
- 1999
How studies write it
Studies that test it under each name
Studies by the year they started
48 studies that test it; most in 2007 (10)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 5 |
| 2005 | 6 |
| 2006 | 8 |
| 2007 | 10 |
| 2008 | 7 |
| 2012 | 4 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 39
- Phase 3
- 8
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 43
M.D. Anderson Cancer Center (7) · Spectrum Pharmaceuticals, Inc (3) · Biogen (2) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (2) · University of Bologna (2) · Fondazione Italiana Linfomi - ETS (1) · SWOG Cancer Research Network (1) · Sheba Medical Center (1)
Often tested with
Tested in the same studies.
Rituximab (12) · Fludarabine (2) · Mitoxantrone (2) · Bortezomib (2) · Patient Observation (1) · Maintenance Therapy (1) · Dexamethasone (1) · Cyclophosphamide (1)
Studies
Open first, then newest update. How each study uses ibritumomab tiuxetan is read from its arms, and is right about nine times in ten.
Testing it · 51
- Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's LymphomaCompletedPhase 4BiogenNCT00168727Written as ibritumomab tiuxetan (Zevalin®)
- Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaStatus unknownPhase 2Joseph TuscanoNCT01811368Written as ibritumomab tiuxetan
- Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent LymphomasCompletedPhase 2M.D. Anderson Cancer CenterNCT00493467Written as Ibritumomab Tiuxetan (Zevalin)
- Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular LymphomaCompletedPhase 3Fondazione Italiana Linfomi - ETSNCT02063685Written as Ibritumomab Tiuxetan + Maintenance
- Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular LymphomaCompletedPhase 2M.D. Anderson Cancer CenterNCT00290511Written as Zevalin
- Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.TerminatedPhase 3Spectrum Pharmaceuticals, IncNCT00322218Written as Zevalin
- S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's LymphomaCompletedPhase 2SWOG Cancer Research NetworkNCT00070018Written as Yttrium-90 ibritumomab tiuxetan
- Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyTerminatedPhase 3Spectrum Pharmaceuticals, IncNCT01510184Written as Zevalin
- Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)TerminatedPhase 3Spectrum Pharmaceuticals, IncNCT01662102Written as Zevalin
- Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell TransplantationCompletedPhase 2M.D. Anderson Cancer CenterNCT00591630Written as Zevalin
- Zevalin-beam for Aggressive LymphomaCompletedPhase 3Sheba Medical CenterNCT00491491Written as ibritumomab tiuxetan
- Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)CompletedPhase 2M.D. Anderson Cancer CenterNCT01490723Written as 111In Ibritumomab
- ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)CompletedPhase 2PETHEMA FoundationNCT00662948Written as Ibritumomab tiuxetan
- Ibritumomab Tiuxetan (Zevalin)+ Rituximab MaintenanceTerminatedPhase 2University of Wisconsin, MadisonNCT00582166Written as Ibritumomab Tiuxetan (Zevalin) + Rituximab
- Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular LymphomaCompletedPhase 2The Christie NHS Foundation TrustNCT01493479Written as 90Y Ibritumomab tiuxetan
- Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular LymphomaTerminatedPhase 1/2Northwestern UniversityNCT00372905Written as Ibritumomab tiuxetan
- Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedPhase 1Swiss Group for Clinical Cancer ResearchNCT00392691Written as ibritumomab tiuxetan
- Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT00012298Written as yttrium Y 90 ibritumomab tiuxetan
- Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)CompletedPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT00644371Written as Ibritumomab Tiuxetan (Zevalin)
- Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)CompletedPhase 2University Hospital, BordeauxNCT00607854Written as Ibritumomab Tiuxetan (Zevalin)
See all 51 studies that test ibritumomab tiuxetan →
Given in every arm · 1 — ibritumomab tiuxetan is usual care beside what is tested
Codes
What other systems call ibritumomab tiuxetan · ClinicalTrials.gg INT004320
- MeSH (NLM) C422802ibritumomab tiuxetanOne source NLM
- UNII (FDA) 4Q52C550XKIBRITUMOMAB TIUXETANConfirmed FDA, NLM, Wikidata
- RxNorm 262323Confirmed FDA, Wikidata
- Wikidata Q635415ibritumomabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29981Ibritumomab TiuxetanConfirmed FDA, Wikidata
- DrugBank DB00078One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C422802 | ibritumomab tiuxetan | One source NLM |
| UNII (FDA) | 4Q52C550XK | IBRITUMOMAB TIUXETAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 262323 | — | Confirmed FDA, Wikidata |
| Wikidata | Q635415 | ibritumomab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29981 | Ibritumomab Tiuxetan | Confirmed FDA, Wikidata |
| DrugBank | DB00078 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.